Objective: To identify the functional and pathologic correlates underlying subjective memory complaints (SMCs) in cognitively normal older adults.
Subjective memory complaint (SMC) is defined by self-reports of memory worsening and objective memory performance in the normal adjusted range. SMCs are common in the elderly population without dementia, with an estimated prevalence range between 22% and 56%, 1 and have been associated with increased risk of incident Alzheimer disease (AD). 2 Despite the high prevalence of self-perceived changes in memory among older adults, relatively little is known about its functional and pathologic correlates, especially in the preclinical stages of AD. This information is crucial because SMCs alone may have insufficient sensitivity and specificity to predict the development of dementia.
With regard to SMCs and b-amyloid (Ab; one hallmark of AD pathology most commonly used to define the preclinical stage), previous studies have found conflicting results. Whereas most studies have reported an association between SMCs and Ab, [3] [4] [5] [6] others could not demonstrate this relationship. 7 Previous studies with fluorodeoxyglucose (FDG)-PET, a biomarker supposed to reflect neuronal integrity, 8 have demonstrated hypometabolism when comparing cognitively normal (CN) individuals with and without SMCs, but the results have been inconsistent as to which brain regions show hypometabolism, e.g., the precuneus, 9 parietotemporal and parahippocampal gyrus, 10 or periventricular region. 11 These inconsistent patterns of FDG-PET hypometabolism could be due to several factors, including the use of different techniques to measure SMCs. In addition, although FDG metabolism has been studied in groups of individuals with and without SMCs, correlation between continuous measures of self-reported complaints and FDG metabolism has never been assessed. Because the degree of memory complaints varies greatly within older adults, investigating the changes in metabolic function that covary with self-appraisal of memory function may shed some additional light on the brain substrate underlying SMCs. Lastly, the contribution of Ab pathology to the functional metabolic correlates of SMCs in CN elders also remains to be elucidated. This information would improve our ability to understand whether SMCs may have prognostic meaning.
The objective of the present study is to further our understanding of the functional and pathologic substrate underlying SMCs by investigating the relationship between selfreported measures of memory function and functional brain metabolism in a large cohort of CN older adults with known Ab status. We hypothesized that the metabolic consequences of SMCs might depend on the presence of Ab pathology and that the occurrence of different FDG patterns might help us better distinguish between SMCs due to decline in cognitive aging from preclinical AD. 16 In this subscale, the person is asked, "How often does remembering or doing the following things present a problem for you?" On each item, the person rates his/her subjective experience on a Likert scale ranging from 1 (always) to 7 (never). The scale was then transformed to numbers ranging from 0 to 6, and the raw scores were Table 1 Demographics of the whole sample and by groups converted to z scores for each participant with the use of the mean and SD from the whole group. Finally, z scores were then reversed by multiplying each value by 21 so that a higher score indicates increased complaints.
METHODS
Ab Pittsburg compound B-PET processing. Pittsburg compound B (PiB)-PET data were processed with SPM8 (Wellcome Department of Cognitive Neurology, London, UK) using a protocol similar to that described in our previous publication. 17 PiB images were realigned, and the first 8 minutes of data were averaged and used to normalize data to the Montreal Neurologic Institute 18 F-fluorodeoxyglocuse template. Distribution volume ratio images were created with Logan plotting (40-to 60-minute interval, gray matter cerebellum reference region). An aggregate of cortical regions that typically have elevated PiB burden in patients with AD, including frontal, lateral temporal and parietal, and retrosplenial cortices, was used to extract a mean PiB value for each participant. A gaussian mixture model approach, as described previously, 18 was used to classify individuals as having high or low Ab burden. The model estimated a cutoff of PiB distribution volume ratio .1.2 for the high-Ab group.
FDG-PET acquisition and processing. FDG was acquired at the MGH PET department (Boston, MA) according to previously published guidelines. 19 FDG was acquired from 45 to 75 minutes after a 5-to 10-mCi bolus injection 6 times in 5-minute frames. To evaluate the anatomy of PET binding, each individual PET data set was rigidly coregistered to the participant's MRI data with SPM8. Additional preprocessing steps included spatial normalization to the Montreal Neurologic Institute space (resampled voxel size 2 3 2 3 2 mm) with the parameters estimated from the corresponding T1-weighted MRI and quantitative scaling with the cerebellum gray matter as reference to obtain standardized uptake volume ratio images. The resulting images were used in the correlation analyses with the SMC score. Region-of-interest analysis. Structural images were processed with Freesurfer version 5.1 (http://surfer.nmr.mgh.harvard.edu) to identify gray, white, and pial surfaces to permit region-ofinterest (ROI) parcellation based on the Desikan-Killiany atlas. Manual quality control of the automated segmentation was performed on all participants. Three participants, 2 Ab 2 and 1 Ab 1 , were excluded from ROI analyses because of insufficient MRI quality. The cortical ribbon and subcortical ROIs defined by MRI were transformed into the FDG-PET native space to obtain FDG standardized uptake volume ratio values in the Freesurferdefined ROI. Data were averaged within each right-left hemisphere ROI pair. ROIs were selected according to the voxel-wise results to control for additional covariates, including structural data. figure  1A ) demonstrated that more complaints (increased z score) were related to decreased FDG metabolism across all participants ( figure 2, A Whole-brain voxel-wise correlations to examine SMCs as a predictor of glucose uptake (FDG-PET) and the interaction effect with Ab (A) A statistically significant correlation, using a pFDR ,0.05 corrected, equal to an uncorrected p 5 0.0003, t 5 3.45, of SMCs and metabolism was found in several associative neocortical regions, including bilateral precuneus (white circle), bilateral inferior parietal lobes, and bilateral middle frontal gyrus (white circle). Note the empty green circles. Color bar depicts threshold from minimum t 5 3.455 to maximum t 5 5.077 in the map. (B) SMC by amyloid status interactions were found bilaterally in the middle temporal lobe (green circle), including parahippocampal gyrus, hippocampus, and entorhinal cortex, and the left mid cingulum (green circle). pFDR ,0.05 corrected, equal to an uncorrected p 5 0.00002, F 5 8. DISCUSSION The present study investigated the functional and pathologic correlates underlying SMCs by combining measures of regional brain metabolism (as measured with FDG-PET) and Ab burden (as measured with PiB-PET). Our results demonstrate that SMCs in CN older adults are related to reduced metabolism in cortical midline regions, which are brain structures known to play a role in self-referential processing. 20 The MTL, a region known to be involved in memory performance, related to SMCs only in the participants who had high Ab, a pattern that suggests that SMCs have different functional correlates according to Ab status. Specifically, decreased MTL metabolism may be a specific marker of subclinical changes in cognition in preclinical AD.
Statistics. Differences in demographic and
Consistent with our expectation and prior published results, 4 we found that Ab 1 individuals had more SMCs than Ab 2 individuals. No difference was found between the groups in regard to sex, education, global cognition, or depression, although the Ab 1 individuals were slightly older than the Ab 2 individuals. The current data reinforce the notion that SMCs may be a useful marker to identify individuals who might be in the preclinical stages of AD.
In line with this, we recently reported that when multiple biomarkers were combined, those CN older individuals who exhibited either increased Ab burden or neurodegeneration (smaller hippocampal volume or decreased FDG metabolism in a set of AD-vulnerable regions) had a statistically significant higher report of SMCs when compared to biomarker-negative CN individuals. 3 In our previous study, we operationalized Ab and neurodegeneration groups by using cutoffs of predefined regions. In the current study, we went one step further by trying to characterize the brain substrate underlying SMCs. Specifically, to unveil the brain metabolic correlates of SMCs, we used an exploratory approach by entering the individual SMCs scores and performed a whole-brain voxel-vise correlation in individual FDG-PET maps.
Our findings demonstrate that self-appraisal of memory function, more specifically, increased SMCs, was associated with decreased glucose metabolism in the posterior (precuneus) and anterior (MFG) midline regions, as well as the bilateral inferior parietal lobes and the right inferior temporal lobe. Interestingly, with regard to the midline regions, evidence from several lines of research has converged on the same set of brain regions (including the ventromedial prefrontal, medial parietal, and posterior cingulate cortex and the inferior parietal lobule) implicated in self-referential processing. 20, 21 With regard to the pathophysiology of AD, mounting evidence has demonstrated the vulnerability of the same cortical midline brain regions to AD-like changes, including early Ab deposition 22 decreased glucose metabolism, 23, 24 structural changes 24, 25 and functional disruption. [26] [27] [28] [29] The convergence of these effects was further pointed out by Buckner et al., 24, 30 who proposed that these cortical brain regions, including the MTL, may be part of a network, the disruption of which contributes to memory impairment. Although the relationships between the hippocampus and the cortical midline regions are not yet fully elucidated, the parahippocampal gyrus could play a critical role in linking these regions together. 31 With regard to FDG metabolism, previous studies showed that hippocampal metabolism is closely related to memory performance. That is, previous studies have shown that hippocampal metabolism is preserved in preclinical AD but decreased in prodromal AD. 32 In contrast and concurrent with the present results, precuneus metabolism has been shown to decrease in the preclinical AD stage, before the onset of cognitive impairment. 19 However, the specificity of precuneus FDG in AD dementia has been criticized because it has been shown that Ab 2 individuals with mild cognitive impairment also exhibit hypometabolism in this region. 33 Interestingly, our main effect of SMCs in the midline regions did not survive when we added depression (GDS) to the model, suggesting that some of the observed changes in the posterior midline regions might be due to depressive symptoms. Indeed, previous findings from our group have indicated a relationship between higher GDS score and FDG hypometabolism in AD-vulnerable regions, including the precuneus in CN older adults. 34 In contrast, we found that the interaction effect between SMCs and Ab pathology remained significant after controlling for age, GDS, and hippocampal volume in the model, supporting the idea that the observed decreased MTL metabolism may be a specific marker of subclinical changes in cognition due to amyloid pathology, above and beyond depressive symptoms. Noteworthy is the finding that the relationship between SMCs and metabolism was affected by amyloid burden in the hippocampus, an area with relatively little amyloid deposition, but not in the precuneus, an area with high amyloid deposition. These findings complement previous functional neuroimaging studies in patients with mild cognitive impairment demonstrating functional abnormalities in the MTL during memory task performance (for review, see reference 35) , indicating that this region is a site of very early pathology in AD, e.g., neurofibrillary tangles. Thus, the observed finding of hypometabolism in the MTL is consistent with the expected effects of progressive AD pathology, resulting in increased neurodegenerative processes, e.g., neurofibrillary tangles. The recent advent of tau-PET imaging in conjunction with PiB-PET will enable future studies to provide regionally specific information about the underlying distribution of AD pathology to shed further light on this issue.
The current results are also in concordance with a previous study by Mosconi et al. 10 demonstrating FDG hypometabolism in the parahippocampus in CN older individuals with an APOE e4 allele and SMCs, further supporting the idea that alterations in the MTL may be a specific marker of subclinical changes in cognition in preclinical AD. Although we were not able to unravel the relationships among genotype, amyloid, SMCs, and metabolism in the current study, we did find, in line with the findings of Mosconi et al., a significantly increased percentage of APOE e4 carriers in the Ab 1 group (61.4%).
We acknowledge that there are several limitations to this study. First, to date, there is no consensus on how to assess SMCs. 36 Previous studies have used methods ranging from nonstandardized clinical interviews to well-validated scales, as well as having the complaints corroborated by an informant. In this study, we used the Memory Functioning Questionnaire to create a subjective memory score. Although this test does not include an informant version, future studies will use other subjective memory questionnaires to investigate potential discrepancies between the participant's self-report and the report of the informant to gain insight into the self-awareness of these memory problems in our participants and how that is related to Ab and FDG metabolism. Second, we are aware that self-reports on cognitive decline could be influenced by confounding factors, for instance, substance use, medication, or other neurologic and medical conditions. In the current study, a history of neurologic or major psychiatric disorder, the use of medications that affect cognitive function, and alcohol and substance abuse were used as exclusion criteria. In addition, none of the participants met criteria for depression. However, other factors that could have influenced the results such as personality traits, anxiety, and hypochondria were not considered in this study.
These findings add to existing literature by demonstrating the importance of obtaining measures of biomarkers in addition to subjective report of memory complaints because they may help distinguish between SMCs due to decline in cognitive aging from preclinical AD dementia.
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